Results: There were 2,159 patients who underwent bariatric surgery with 1,324 (61%) patients in the heparin group and 835 (39%) in the enoxaparin group. Chi-square test was used to test for differences between groups. Postoperative bleeding was defined as requiring a blood transfusion or reoperation for bleeding within 30 days of surgery. Heparin was given from March 2012 through February 2018 and enoxaparin from March 2018 through December 2021 for pre and postoperative VTE prophylaxis. All patients 18 years or older who underwent primary bariatric surgery (sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB)) at a single institution between March 2012 and December 2021 were included. Methods: This retrospective cohort study was performed using a prospective clinical database maintained by a trained abstractor for the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. The objective of this study was to determine if this change in VTE prophylaxis was associated with differing rates of postoperative bleeding and VTE occurrence after bariatric surgery. In March 2018, our bariatric program switched from heparin to enoxaparin for perioperative VTE prophylaxis, creating a natural experiment. However, few data exist comparing efficacy and bleeding risk of VTE prophylaxis medications. Introduction: Perioperative venothromboembolism (VTE) chemoprophylaxis is an established tenant of bariatric surgery. Teitelbaum, MD, MEd 1 1Northwestern University Department of Surgery Reiter, MD, MPH 1 Joanne Prinz, RN, BSN 1 Alexander P. Increased Bleeding Risk with Enoxaparin Venothromboembolism Prophylaxis Compared with Heparin in Patients Undergoing Bariatric Surgery Audra J.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |